Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases

NCT05742425 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Unresectable Colon Cancer Peritoneal Metastases
PMMR/Ras/BRAF Wild-type

Interventions

DRUG: Serplulimab Combined With FOLFIRI and Bevacizumab

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Collaborators

[object Object]